all report title image
  • Published On : Aug 2022
  • Code : CMI5181
  • Industry : Pharmaceutical
  • Pages : 171
  • Formats :

The global Alzheimer’s disease diagnostics and therapeutics market was valued at US$ 5,933.5 Mn in 2021 and is forecast to reach a value of US$ 8,603.9 Mn by 2028 at a CAGR of 5.6% between 2022 and 2028. The global Alzheimer’s disease diagnostics and therapeutics market is experiencing strong growth due to the increase in disease burden, growing geriatric population, and increase in demand for novel diagnostics and therapeutics. Moreover, increase in focus on the development of novel diagnostics and therapeutics and rise in awareness among people about Alzheimer’s disease diagnostics and therapeutics is expected to boost the growth of the Alzheimer’s disease diagnostics and therapeutics market.

Global Alzheimer's Disease Diagnostics and Therapeutics Market: Regional Insights

Based on geography, the global Alzheimer’s disease diagnostics and therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

Among regions, North America is expected to gain highest share in the market over the forecast period owing to the increasing prevalence of Alzheimer’s disease in this region, especially in the United States. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2020, more than 5.8 million people in the United States were living with Alzheimer's disease. The number of people living with the disease doubles every five years beyond age 65, and this number is projected to nearly triple to 14 million people by 2060.

Moreover, Asia Pacific is expected to witness robust growth in the global Alzheimer’s disease diagnostics and therapeutics market due to the increasing awareness among people and increase in prevalence of Alzheimer’s disease in this region. For instance, according to the Alzheimer's Association (India), more than 60% of people with dementia are from low and middle income countries like India. This number will rise to more than 70% by 2050.

Figure 1. Global Alzheimer's Disease Diagnostics and Therapeutics Market Share (%), by Region, 2021

Alzheimers Disease Diagnostics and Therapeutics  | Coherent Market Insights

Global Alzheimer's Disease Diagnostics and Therapeutics Market Drivers:

Increasing prevalence of Alzheimer’s disease around the world is expected to boost the growth of the global Alzheimer’s disease diagnostics and therapeutics market over the forecast period. For instance, according to the World Health Organization (WHO), currently, around 55 million people live with dementia worldwide, and there are nearly ten million new cases every year. According to the same source, Alzheimer's disease is the most common form of dementia and may contribute to 60-70% of cases of dementia.

Increasing demand for novel diagnostic tools due to rise in prevalence of Alzheimer’s disease across the globe is expected to augment growth of the global Alzheimer’s disease diagnostics and therapeutics market over the forecast period. For instance, after proving that its blood test to measure the level of amyloid plaques in the brain matches up to the results of PET scans in predicting the onset of Alzheimer’s, C2N Diagnostics is expanded its slate of Alzheimer’s screening tools. In May 2022, C2N Diagnostics launched the new Research Use Only (RUO) test to support the diagnosis and treatment of Alzheimer's disease.

CMI table icon

Alzheimer's Disease Diagnostics and Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 6,206.3 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2028
Forecast Period 2022 to 2028 CAGR: 5.6% 2028 Value Projection: US$ 8,603.9 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product: Therapeutics [Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Other Therapeutics] and Diagnostics [Brain Imaging and CSF Test for Alzheimer’s Disease]
Companies covered:

Luye Pharma Group, Vigil Neuroscience, Grifols SA, Corium International Inc., Adamas Pharmaceuticals Inc., Abbvie Inc., Merz Pharma, Zydus Cadila, Siemens Healthineers AG, Apotex Inc., Lupin Limited, Eli Lilly & Company, Johnson & Johnson, Biogen Inc., Eisai Co. Ltd., Pfizer Inc., Merck & Co. Inc., Novartis AG, Hoffmann-La Roche Ltd., and Teva Pharmaceutical Industries Ltd., among others

Growth Drivers:
  • Increasing prevalence of Alzheimer’s disease
  • Increasing demand for novel diagnostic tools
Restraints & Challenges:
  • Lack of surrogate markers and challenges in early diagnosis
  • High failure rates of late-stage Alzheimer’s drugs

Global Alzheimer's Disease Diagnostics and Therapeutics Market Opportunities:

Increasing demand for safe and effective Alzheimer’s disease therapeutics is expected to offer significant growth opportunities for players in the global Alzheimer’s disease diagnostics and therapeutics market. For instance, in June 2021, Eli Lilly and Company announced that the U.S. Food and Drug Administration (USFDA) has granted breakthrough therapy designation for donanemab, its investigational antibody therapy for the treatment of Alzheimer disease. The company also intend to submit a biologics license application under accelerated approval pathway later this year based on data from the phase 2 study.

Increasing awareness among people about novel diagnostics and therapeutics is expected to offer lucrative growth opportunities for players in the global Alzheimer’s disease diagnostics and therapeutics market. For instance, in March 2021, the Alzheimer’s Association launched More Time, a campaign to increase awareness and demonstrate the strong desire by those living with or facing Alzheimer's for a disease-modifying treatment. The campaign included full-page print advertising, digital advertising, social media and email marketing, as well as online town hall meeting. People affirmed their support over 1.1 million times, and the campaign received more than 90 million media impressions.

Global Alzheimer's Disease Diagnostics and Therapeutics Market Trends:

Increase in development of novel diagnostics and therapeutics is expected to propel growth of the global Alzheimer’s disease diagnostics and therapeutics market. For instance, in May 2022, the U.S. Food and Drug Administration (FDA) authorized the first in vitro diagnostic to help diagnose early Alzheimer’s disease. The novel test minimizes radiation risks to patients who otherwise would need to be tested with positron emission tomography (PET) scans.

Growing geriatric population around the world is expected to aid in the growth of the global Alzheimer’s disease diagnostics and therapeutics market. For instance, the risk of developing Alzheimer's disease increases with age. As the number of older Americans grows rapidly, so too will the number of new and existing cases of Alzheimer's. According to the Alzheimer’s Association, by 2050, the number of people age 65 and older with Alzheimer’s may grow to a projected 12.7 million.

Global Alzheimer's Disease Diagnostics and Therapeutics Market Restraints:

Lack of surrogate markers and challenges in early diagnosis is expected to hamper growth of the Alzheimer’s disease diagnostics and therapeutics market. For instance, early diagnosis of Alzheimer's has been challenging, as early symptoms of the disease are usually ignored because they are relatively mild. Therefore, any diagnostic and therapeutic care cannot be given to the patient, and this can possibly restrict the growth of the market.

High failure rates of late-stage Alzheimer’s drugs is expected to hinder the growth of the global Alzheimer’s disease diagnostics and therapeutics market. The failure rate of Alzheimer's drug development has remained unchanged for decades, with 99% of trials showing no difference between both the drug and placebo. This figure is especially high, considering the ever-growing number of drug candidates in the pipeline.

Figure 2. Global Alzheimer's Disease Diagnostics and Therapeutics Market Share (%), by Product, 2021

Alzheimers Disease Diagnostics and Therapeutics  | Coherent Market Insights

Global Alzheimer's Disease Diagnostics and Therapeutics Market Segmentation:

The global Alzheimer’s disease diagnostics and therapeutics market report is segmented into Product and Region.

Based on Product, the market is segmented into Therapeutics and Diagnostics. Out of which, Both Therapeutics and Diagnostics Segments are expected to dominate the Alzheimer’s disease diagnostics and therapeutics market over the forecast period and this is attributed to the rise in prevalence of Alzheimer’s disease.

Alzheimer’s disease diagnostics - brain scans, such as computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET), help diagnose Alzheimer's or rule out other possible causes for symptoms.

Alzheimer’s disease therapeutics - there's no cure, but there are treatments that may change disease progression, and drug and non-drug options that may help treat symptoms.

Global Alzheimer's Disease Diagnostics and Therapeutics Market: Key Developments

In March 2021, Roche and GenMark Diagnostics Inc. signed a definitive merger agreement to access novel technologies to test a broad range of pathogens with one patient sample.

In July 2020, UCB signed exclusive license agreement with Roche and Genentech, a member of the Roche Group, for the development and commercialization of UCB0107, an innovative anti-Tau antibody treatment for Alzheimer’s disease (AD).

In January 2020, Sandoz acquired the Japanese business unit of Aspen Global Incorporated, consisting of off-patent branded medicines, with a focus on anesthetics and specialty brands.

Global Alzheimer's Disease Diagnostics and Therapeutics Market: Key Companies Insights

The global Alzheimer’s disease diagnostics and therapeutics market is highly competitive. This is attributed to the rise demand for safe and effective diagnostics and therapeutics and growing geriatric population across the globe.

Some of the key players in the global Alzheimer’s disease diagnostics and therapeutics market are Luye Pharma Group, Vigil Neuroscience, Grifols SA, Corium International Inc., Adamas Pharmaceuticals Inc., Abbvie Inc., Merz Pharma, Zydus Cadila, Siemens Healthineers AG, Apotex Inc., Lupin Limited, Eli Lilly & Company, Johnson & Johnson, Biogen Inc., Eisai Co. Ltd., Pfizer Inc., Merck & Co. Inc., Novartis AG, Hoffmann-La Roche Ltd., and Teva Pharmaceutical Industries Ltd., among others.

*Definition: Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens. Symptoms of AD eventually grow severe enough to interfere with daily tasks. Brain scans help diagnose AD. There's no cure, but there are treatments that may change disease progression and help treat symptoms.

Alzheimer's disease is a neurodegenerative disease that usually starts slowly and progressively worsens. It is a progressive form of dementia, a continuous decline in thinking, behavioral, and social skills that disrupts a person's ability to function independently. Doctors perform a series of tests to rule out other possible causes of impairment. It can be diagnosed in several different ways. Imaging techniques, such as CT and MRI, are primarily used to rule out other conditions that may cause symptoms similar to Alzheimer's but require different treatment. There's no cure for Alzheimer's disease, but there are treatments that may change disease progression, and drug and non-drug options that may help treat symptoms. Aducanumab is the only disease-modifying medication currently approved to treat Alzheimer's.

Market Dynamics:

Increasing use of biomarkers in Alzheimer’s diagnosis and drug development and increasing focus on the development of novel diagnostics & therapeutics due to increase in disease burden is expected to boost the growth of the global Alzheimer’s disease diagnostics and therapeutics market. For instance, in in June 2021, the Alzheimer’s Drug Discovery Foundation (ADDF) Diagnostics Accelerator launched four new research investments for the development of digital biomarkers for Alzheimer's diagnosis. Moreover, in August 2022, the Alzheimer's Association announced the launch of Alzheimer's Network for Treatment and Diagnostics (ALZ-NET), a platform to collect long-term clinical and safety data from patients treated with FDA-approved Alzheimer's disease therapies in real world clinical settings. It is the first network developed specifically for FDA-approved Alzheimer's treatments, collecting real-world evidence on drug effectiveness and side effects over a long period of time.

Key features of the study:

  • This report provides in-depth analysis of the global Alzheimer’s disease diagnostics and therapeutics market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022–2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global Alzheimer’s disease diagnostics and therapeutics market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Luye Pharma Group, Vigil Neuroscience, Grifols SA, Corium International Inc., Adamas Pharmaceuticals Inc., Abbvie Inc., Merz Pharma, Zydus Cadila, Siemens Healthineers AG, Apotex Inc., Lupin Limited, Eli Lilly & Company, Johnson & Johnson, Biogen Inc., Eisai Co. Ltd., Pfizer Inc., Merck & Co. Inc., Novartis AG, Hoffmann-La Roche Ltd., and Teva Pharmaceutical Industries Ltd., among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global Alzheimer’s disease diagnostics and therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Alzheimer’s disease diagnostics and therapeutics market.

Detailed Segmentation:

  • Global Alzheimer's Disease Diagnostics and Therapeutics Market, By Product:
    • Therapeutics
    • Cholinesterase Inhibitors
    • NMDA Receptor Antagonists,
    • Other Therapeutics
    • Diagnostics
    • Brain Imaging
    • SF Test for Alzheimer’s Disease
  • Global Alzheimer's Disease Diagnostics and Therapeutics Market, By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America

Frequently Asked Questions

The global Alzheimer’s disease diagnostics and therapeutics market size is estimated to be valued at US$ 6,206.3 Million in 2022 and is expected to exhibit a CAGR of 8,603.9 between 2022 and 2028.
Increasing prevalence of Alzheimer’s disease and increasing demand for novel diagnostic tools is fueling the growth of the market.
The Therapeutics segment is the leading productt segment in the market.
Lack of surrogate markers and challenges in early diagnosis and high failure rates of late-stage Alzheimer’s drugs are some major factors restraining growth of the market.
Major players operating in the market are Luye Pharma Group, Vigil Neuroscience, Grifols SA, Corium International Inc., Adamas Pharmaceuticals Inc., Abbvie Inc., Merz Pharma, Zydus Cadila, Siemens Healthineers AG, Apotex Inc., Lupin Limited, Eli Lilly & Company, Johnson & Johnson, Biogen Inc., Eisai Co. Ltd., Pfizer Inc., Merck & Co. Inc., Novartis AG, Hoffmann-La Roche Ltd., and Teva Pharmaceutical Industries Ltd., among others.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo